What is HC Wainwright’s Forecast for GRCE FY2025 Earnings?

Grace Therapeutics, Inc. (NASDAQ:GRCE) – Research analysts at HC Wainwright issued their FY2025 EPS estimates for Grace Therapeutics in a research note issued to investors on Tuesday, February 18th. HC Wainwright analyst O. Livnat anticipates that the company will post earnings of ($1.14) per share for the year. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Grace Therapeutics’ current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for Grace Therapeutics’ Q4 2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $1.68 EPS.

Grace Therapeutics Trading Down 2.9 %

NASDAQ:GRCE opened at $3.29 on Thursday. The business’s 50-day moving average price is $3.65. The firm has a market capitalization of $33.36 million, a price-to-earnings ratio of -2.84 and a beta of 1.36. Grace Therapeutics has a 52-week low of $2.13 and a 52-week high of $4.97.

Grace Therapeutics (NASDAQ:GRCE) last issued its quarterly earnings data on Thursday, February 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01.

Grace Therapeutics Company Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.